GLUA3 Antibody

Frontotemporal Dementia (FTD)

• Prevalence: 23.4% of FTD patients show anti-GluA3 antibodies in serum .

• Clinical features: Associated with presenile onset, behavioral variant FTD, and bitemporal atrophy .

• Pathological effects:

  • ↓ Synaptic GluA3 levels in postmortem FTD brains .

  • ↑ Neuronal Tau and TDP-43 expression in human iPSC-derived neurons .

Table 1: Anti-GluA3 Antibody Prevalence in FTD Patients

Animal Models

• Behavioral deficits: Mice injected with patient-derived anti-GluA3 IgG exhibited:

  • Recognition memory impairment .

  • Social cognitive dysfunction .

• Synaptic changes:

  • Transient dendritic spine loss in PFC .

  • Postsynaptic tau accumulation .

Table 2: Preclinical Outcomes of Anti-GluA3 IgG Administration

Applications in Research

• Western blot: Detects ~100 kDa bands in cerebellum, hippocampus .

• Immunohistochemistry: Localizes GluA3 to Bergmann glia and Purkinje cells .

• Live-cell imaging: Tracks AMPAR trafficking in neurons .

Therapeutic Implications

• AMPA receptor modulation: Positive allosteric modulators reverse synaptic deficits in mice .

• Immunotherapy: Intravenous immunoglobulin (IVIg) improved symptoms in autoimmune encephalitis .

Key Research Gaps

• Long-term effects of anti-GluA3 antibodies in chronic neurodegeneration.

• Mechanisms linking autoimmunity to Tau pathology in FTD .